Kevin Feeley - 16 Dec 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Dec 2024, 18:21:20 UTC
Prior SEC filing
11 Dec 2024
Next SEC filing
06 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Bridget Brown, Attorney-in-Fact

Key filing fact

Kevin Feeley filed Form 4 for GeneDx Holdings Corp. (WGS) on 18 Dec 2024.

Key facts

  • This page summarizes Kevin Feeley's Form 4 filing for GeneDx Holdings Corp. (WGS).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Dec 2024, 18:21.

Change

  • Previous filing in this sequence was filed on 11 Dec 2024.
  • Current net transaction value: -$286,139.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WGS transaction

Class A Common Stock

Options Exercise

Transaction value
$0
Shares
+7,197
Change %
+29%
Price
$0.000000
Shares after
31,928
Date
16 Dec 2024
Ownership
Direct
Footnotes
F1
WGS transaction

Class A Common Stock

Sale

Transaction value
$286,139
Shares
-3,728
Change %
-12%
Price
$76.75
Shares after
28,200
Date
16 Dec 2024
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WGS transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-7,197
Change %
-10%
Price
$0.000000
Shares after
64,772
Date
16 Dec 2024
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
7,197
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F3

6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .